Clinical, biochemical, acid-base, and electrolyte abnormalities in cats after hypertonic sodium phosphate enema administration.
Ten clinically healthy cats were allotted into 2 groups. Group A was given the low (60 ml), and group B was given the high (120 ml) recommended dose of a commercial hypertonic sodium phosphate enema. Enema retention was enforced. All cats developed clinical and/or laboratory abnormalities, with group B cats being more severely affected. Clinical signs that occurred rapidly included depression, ataxia, vomition, bloody diarrhea, mucous membrane pallor, and stupor; tetany was not seen. One cat in group B died. Laboratory abnormalities included hypernatremia, hyperphosphatemia, hypocalcemia, hyperglycemia, calculated hyperosmolality, and metabolic acidosis with high anion gap probably due to hyperlacticacidemia. There were no significant gross or microscopic lesions associated with enema administration. Therefore, the use of hypertonic sodium phosphate enema at recommended doses is potentially dangerous to cats.
D000138:Acidosis / Q000097:blood / Q000139:chemically induced / Q000662:veterinary*; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002118:Calcium / Q000097:blood; D002371:Cat Diseases / Q000097:blood / Q000139:chemically induced*; D002415:Cats; D004195:Disease Models, Animal; D004733:Enema / Q000662:veterinary*; D005260:Female; D006982:Hypertonic Solutions; D007773:Lactates / Q000097:blood; D008297:Male; D009994:Osmolar Concentration; D010710:Phosphates / Q000009:adverse effects* / Q000097:blood; D012449:Safety; D012964:Sodium / Q000097:blood
D001786:Blood Glucose; D006982:Hypertonic Solutions; D007773:Lactates; D010710:Phosphates; D012964:Sodium; C018279:sodium phosphate; D002118:Calcium